These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17011503)

  • 21. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes.
    Li G; Leff T
    Mol Endocrinol; 2007 Apr; 21(4):857-64. PubMed ID: 17227883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization, transcriptional activity and nutritional regulation of peroxisome proliferator activated receptor gamma in Nile tilapia (Oreochromis niloticus).
    He AY; Liu CZ; Chen LQ; Ning LJ; Qin JG; Li JM; Zhang ML; Du ZY
    Gen Comp Endocrinol; 2015 Nov; 223():139-47. PubMed ID: 26002036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of CUL4B in Adipocytes Promotes PPARγ-Mediated Adipose Tissue Expansion and Insulin Sensitivity.
    Li P; Song Y; Zan W; Qin L; Han S; Jiang B; Dou H; Shao C; Gong Y
    Diabetes; 2017 Feb; 66(2):300-313. PubMed ID: 27899484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of aging on the expression of peroxisome proliferator-activated receptor gamma and the possible relation to insulin resistance.
    Ye P; Zhang XJ; Wang ZJ; Zhang C
    Gerontology; 2006; 52(2):69-75. PubMed ID: 16508313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
    Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
    Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into TNFα/PTP1B and PPARγ pathway through RNF213- a link between inflammation, obesity, insulin resistance, and Moyamoya disease.
    Sarkar P; Thirumurugan K
    Gene; 2021 Mar; 771():145340. PubMed ID: 33333224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAZ Is a Negative Regulator of PPARγ Activity in Adipocytes and TAZ Deletion Improves Insulin Sensitivity and Glucose Tolerance.
    El Ouarrat D; Isaac R; Lee YS; Oh DY; Wollam J; Lackey D; Riopel M; Bandyopadhyay G; Seo JB; Sampath-Kumar R; Olefsky JM
    Cell Metab; 2020 Jan; 31(1):162-173.e5. PubMed ID: 31708444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPARδ, PPARγ, and RXR.
    Li JE; Futawaka K; Yamamoto H; Kasahara M; Tagami T; Liu TH; Moriyama K
    Am J Chin Med; 2015; 43(5):879-92. PubMed ID: 26227398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
    Broekema MF; Massink MPG; Donato C; de Ligt J; Schaarschmidt J; Borgman A; Schooneman MG; Melchers D; Gerding MN; Houtman R; Bonvin AMJJ; Majithia AR; Monajemi H; van Haaften GW; Soeters MR; Kalkhoven E
    Mol Metab; 2019 Feb; 20():115-127. PubMed ID: 30595551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.
    Park Y; Freedman BD; Lee EJ; Park S; Jameson JL
    Diabetologia; 2003 Mar; 46(3):365-77. PubMed ID: 12687335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
    Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
    J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
    Barroso I; Gurnell M; Crowley VE; Agostini M; Schwabe JW; Soos MA; Maslen GL; Williams TD; Lewis H; Schafer AJ; Chatterjee VK; O'Rahilly S
    Nature; 1999 Dec 23-30; 402(6764):880-3. PubMed ID: 10622252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
    Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
    J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mouse model of conditional lipodystrophy.
    Kim S; Huang LW; Snow KJ; Ablamunits V; Hasham MG; Young TH; Paulk AC; Richardson JE; Affourtit JP; Shalom-Barak T; Bult CJ; Barak Y
    Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16627-32. PubMed ID: 17921248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mutations of peroxisome proliferator-activated receptor gamma (PPARgamma): clinical implications].
    Gacka M; Adamiec R
    Postepy Hig Med Dosw (Online); 2004; 58():483-9. PubMed ID: 15765009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPARgamma Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy.
    Saumoy M; Veloso S; Alonso-Villaverde C; Domingo P; Chacón MR; Miranda M; Aragonès G; Gutiérrez MM; Viladés C; Peraire J; Sirvent JJ; López-Dupla M; Aguilar C; Richart C; Vidal F;
    Curr HIV Res; 2009 Sep; 7(5):533-40. PubMed ID: 19534662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action.
    Araki O; Ying H; Furuya F; Zhu X; Cheng SY
    Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16251-6. PubMed ID: 16260719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipodystrophy, Diabetes and Normal Serum Insulin in PPARγ-Deficient Neonatal Mice.
    O'Donnell PE; Ye XZ; DeChellis MA; Davis VM; Duan SZ; Mortensen RM; Milstone DS
    PLoS One; 2016; 11(8):e0160636. PubMed ID: 27505464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.